Form 4: Cue Biopharma CFO Receives Stock Grant
Insider Transaction (Form 4)
James M Ahlers, Chief Financial Officer of Cue Biopharma, Inc., reported multiple transactions in common stock on July 30, 2026.
Summary
- Grant/award: acquired 25,500 Common Stock on July 30, 2026; holds 25,500 after (Direct).
- Grant/award: acquired 51,000 Stock Option (Right to Buy) on July 30, 2026; holds 51,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
James M Ahlers — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-30 | Grant/award | Common Stock | 25,500 | — | — | 25,500 |
| 2026-07-30 | Grant/award | Stock Option (Right to Buy) | 51,000 | — | — | 51,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-30 | Grant/award (25,500 shares) |
| 2026-07-30 | Grant/award (51,000 shares) |
Keywords
insider transaction, Form 4, CUE, Cue Biopharma, Inc., neutral, James M Ahlers
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.